Table 2.
Comparison of CSF biomarkers of AD in various studies.
| Reference | CSF biomarker | Disease comparison | No. of cases (AD/non-AD) | Threshold | Specificity (95% CI) | Sensitivity (95% CI) | AUC | PPV/NPV |
|---|---|---|---|---|---|---|---|---|
| Kapaki et al. (57) | Aβ1-42 | AD versus HC | (49/49) | 490 pg/ml | 0.80 (0.66–0.90) | 0.82 (0.68–0.91) | 0.87 | 0.92/0.6 |
| Aβ1-42 | AD versus NAND | (49/15) | 435 pg/ml | 0.80 (0.52–0.95) | 0.71 (0.57–0.83) | 0.76 | 0.84/0.65 | |
| De Jong et al. (58) | Aβ1-42 | AD versus HC | (61/30) | 603 pg/ml | 0.93 | 0.93 | N/A | 0.97/0.88 |
| Mulder et al. (59) | Aβ1-42 | ProbAD versus HC | (131/248) | 550 pg/ml | 0.83 (0.76–0.89) | 0.85 | 0.93 | N/A |
| Vos et al. (28, 29) | Aβ1-42 | AD versus naMCI | (39/226) | 624 pg/ml | 0.71 (0.57–0.85) | 0.55 (0.33–0.77) | N/A | 0.48/0.76 |
| Aβ1-42 | AD versus aMCI | (132/399) | 550 pg/ml | 0.58 (0.57–0.85) | 0.75 (0.64–0.87) | N/A | 0.56/0.78 | |
| Kapaki et al. (57) | Total tau | AD versus HC | (49/49) | 317 pg/ml | 0.96 (0.86–0.99) | 0.88 (0.75–0.95) | 0.95 | 0.98/0.73 |
| Total tau | AD versus NAND | (49/15) | 437 pg/ml | 0.93 (0.68–0.99) | 0.71 (0.57–0.83) | 0.76 | 0.94/0.68 | |
| De Jong et al. (58) | Total tau | AD versus HC | (61/30) | 352 pg/ml | 0.97 | 0.79 | N/A | 0.98/0.69 |
| Mulder et al. (59) | Total tau | AD versus HC | (131/248) | 427 pg/ml | 0.78 (0.65–0.91) | 0.60 (0.39–0.81) | N/A | 0.57/0.80 |
| Vos et al. (28, 29) | Total tau | AD versus naMCI | (39/226) | 427 pg/ml | 0.78 (0.65–0.91) | 0.60 (0.39–0.81) | N/A | 0.57/0.80 |
| Total tau | AD versus aMCI | (132/399) | 524 pg/ml | 0.61 (0.50–0.72) | 0.74 (0.62–0.85) | N/A | 0.57/0.77 | |
| Kapaki et al. (57) | Aβ1-42/T-tau | AD versus HC | (49/49) | 2.27 | 0.86 (0.73–0.94) | 0.96 (0.86–0.99) | 0.96 | 0.95/0.88 |
| Aβ1-42/T-tau | AD versus NAND | (49/15) | 1.06 | 1.0 (0.78–1.0) | 0.71 (0.57–0.83) | 0.92 | 1.00/0.70 | |
| De Jong et al. (58) | Aβ1-42/T-tau | AD versus HC | (61/30) | 1.895 | 0.95 | 0.97 | N/A | 0.98/0.91 |
| Vos et al. (28, 29) | Aβ1-42/T-tau | AD versus naMCI | (39/226) | 0.96 | 0.54 (0.38–0.69) | 0.90 (0.77–1.00) | N/A | 0.57/0.80 |
| Aβ1-42/T-tau | AD versus aMCI | (132/399) | 0.78 | 0.38 (0.27–0.48) | 0.98 (0.94–1.00) | N/A | 0.57/0.77 | |
| Shaw et al. (60) | Aβ1-42; T-tau with APOE ε4 | AD versus NC | (100/114) | 0.34 | 0.80 | 0.98 | 0.94 | 0.86/0.97 |
Aβ42, amyloid-beta1-42 peptide; AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; HC, healthy control; MCI, mild cognitive impairment; naMCI, non-amnestic mild cognitive impairment; NAND, non-AD neurodegenerative dementias; PPV/NPV, positive predictive value/negative predictive value; T-tau, total tau; CSF, cerebrospinal fluid.